Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (PIV), respiratory syncytial virus, metapneumovirus). It is likely that the alloimmune response triggered by the respiratory virus is inadequate and leads to the peribronchiolar fibrotic process. The objective is to analyze the kinetics of profiles of the blood and respiratory host responses resulting from a high or low parainfluenza respiratory infection, in order to evaluate if the occurrence of a BO is associated with a specific signature We will evaluate the predictive signature of a BO after a parainfluenza virus infection by characterizing the differences between the patients evolving and those not evolving to a BO at 2 months after the infection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults having received a hematopoietic stem cell transplantation for less than two years

• Availability of respiratory function tests prior to infection

• Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and/or lower respiratory tract

• Symptoms of respiratory infection ≤ 5 days

• Signed informed consent

Locations
Other Locations
France
Saint Louis
RECRUITING
Paris
Contact Information
Primary
David Michonneau, MD PhD
david.michonneau@aphp.fr
1 42 49 49 49
Backup
Jérôme Lambert, MD PhD
jerome.lambert@u-paris.fr
142499742
Time Frame
Start Date: 2021-03-01
Estimated Completion Date: 2025-03-01
Participants
Target number of participants: 14
Treatments
Cases
eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months
Controls
eligible patients free of 10% FEV1 decline at 2 months
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov